• E-mail :[email]
  • Phone : +33 5 61 32 56 46
  • Location : Toulouse, France
Last update 2012-09-07 09:46:10.747

Frank LEZOUALC'H PhD Molecular Endocrinology

Course and current status

University degrees and qualifications

Université Paris 6, Pierre & Marie Curie,  Ph.D 1995, Molecular Endocrinology

Max Planck Institute, Postdoc 1996, Molecular Neurobiogy

INSERM U446, Univ Paris Sud-11, Postdoc 1998, Molecular Cardiology

Univ Paris Sud-11,  HDR 2000, Pharmacy

Professional activities

1999     Research associate (CR1) INSERM, INSERM U-446, Univ Paris-Sud 11,   Molecular & Pharmacological Characterisation of human serotonin 5-HT4 receptors

2005      Research Director INSERM (DR2), INSERM U-446, Univ Paris-Sud 11, Epac: a new target for cyclic AMP- Implication in cardiac hypertrophy & heart failure

2006     Head of the team « Small G protein signalling and cardiac pathophysiology” at Inserm UMR-769, Univ Paris-Sud 11, Châtenay-Malabry; Fondation pour la Recherche Médicale, Program « Equipe FRM », 

2010      Head of the team “Cell signalling & cardiac remodelling”; at INSERM U-858, I2MR, Toulouse

Research Area : Identification of new pharmacological targets for the treatment of Heart Failure, Molecular pharmacology & Physiology, Cell signalling


Member of Administrative Council, Fac. Pharmacy, Univ. Paris XI (2004-2005)

Member of Scientific Section 40, Fac. Pharmacy, Univ. Paris XI (2001-2005)

Member of the French National Agency for Research (ANR) Committee (2010-2011)

Member of the Delegation at the Clinical Research and Innovation, Toulouse (2012- )

Reviewer for AERES, ANR, AFM, Health Research Council of New Zealand, WellcomeTrust, Alzheimer's Association, British J. of Pharmacology, Circulation, Circ Res, J. Cell Biology, Molecular Pharmacology

 Valorisation, scientific production, teaching

Author of 5 patents (one under licence), around 70 publications in refereed journals, sum of Times Cited without self-citations: 4936

Mentor of 7 PhD thesis, over 20 invited conferences abroad including ISHR, ESC meetings.

Teaching of master students at Univ Paris Sud-11, UMPC, UPS/ 10h/yr


Scientific summary

F. Lezoualc’h: PhD & HDR, Univ Paris VI & Paris XI , Director of Research at INSERM, Head of a team at Inserm U1048, molecular biologist. More than ten years experience in the identification of new therapeutic targets for the treatment of Alzheimer’s disease and Heart failure, author of 4 patents. Frank Lezoualc’h has been working on the cAMP binding protein Epac since 2003 and is the inventor of the concept that Epac is a new target involved in cardiac hypertrophy leading to heart failure. He is author of the patent “Use of an Epac antagonist of Epac for treating human cardiac hypertrophy” (Patent Inserm) and has therefore a strong expertise in the functional and molecular characterization of this biological target. During his previous activities, he was heading a multidisciplinary project on the pharmacological characterization of the serotonin 5-HT4 receptor with a special emphasis on the role of the 5-HT4 receptor on Amyloid precursor protein processing. 

Image d’exemple